Prescriptions for ADHD Medications Surge During Pandemic, Leading to Shortage
The coronavirus pandemic has caused a significant increase in prescriptions for ADHD medications, resulting in an ongoing shortage that continues to affect patients today. According to a study published in JAMA Psychiatry, prescriptions for ADHD medications jumped by over 14% in a two-year period after the start of the pandemic.
The study revealed that nearly 6 million new prescriptions for stimulants were written in the first two years of the pandemic, representing an increase of approximately 700,000 compared to the previous two years. This surge in prescriptions was primarily driven by a rise in ADHD diagnoses among young adults and women.
ADHD, a neurodevelopmental disorder usually diagnosed in childhood and lasting into adulthood, is characterized by symptoms such as difficulty paying attention, impulsivity, daydreaming, and forgetfulness. The Centers for Disease Control and Prevention (CDC) estimates that around 10% of children between the ages of 3 and 17 have been diagnosed with ADHD, and these numbers have likely increased since 2019.
While there is no cure for ADHD, the condition can be effectively managed through treatments such as medication or therapy. However, the increase in prescriptions has led to a shortage of one of the most commonly prescribed stimulants for ADHD, Adderall. The U.S. Food and Drug Administration (FDA) has declared a nationwide shortage of Adderall, as its production is limited by the Drug Enforcement Administration (DEA), which classifies it as a controlled substance.
An FDA spokesperson stated that several manufacturers of ADHD medications are still facing supply issues. Nonetheless, there are currently nine manufacturers with available supply, and additional stock is expected in the following months. The FDA advises patients to consult with their healthcare providers to determine the best treatment options during this shortage.
Surprisingly, in 2022, only 70% of the allocated quota for Adderall was sold, resulting in the production of a staggering 1 billion doses that were not made or shipped. To address this issue, both the DEA and FDA have called upon manufacturers to increase production and meet the allocated quota amount.
Teva, the largest manufacturer of generic and brand name Adderall in the U.S., reported an unprecedented demand in March 2022, causing intermittent delays for pharmacies and patients. The company is working diligently to meet this surge in demand and minimize any future disruptions in the supply chain.
As the pandemic continues to affect people’s lives, it is vital to prioritize the availability of essential medications. Patients are encouraged to stay in close contact with their healthcare providers and explore alternative treatment options if necessary. By working together, patients and healthcare professionals can navigate this shortage and ensure that individuals with ADHD have access to the medications they need for effective management of their condition.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”